|
Adam G. Lowe became a Director of Oncologix and President and Chief
Operating Officer of Oncologix upon the Merger. He had been a consultant to JDA
from May 2006 until the Merger. Previously, since June 2005, he and Mr. Andrew
Green (see above) were employed by NeoMedica, LLC, a consulting group owned by
them, that specialized in executive level medical device consulting for clients
that included early stage ventures dealing with Class III vascular brachytherapy
devices involving cardiology, ophthalmology, orthopedics, and electrophysiology.Prior to that, from 1999, he was employed by the Novoste Corporation (a publicly traded medical device company) as a corporate officer in the areas of Quality Assurance, Regulatory Affairs and Operations dealing with Class III vascular
brachytherapy devices. Before his employment by Novoste, he was employed by C.R. Bard, Inc. from 1988 until 1991 and again from 1993 until 1999 in various quality assurance positions in the areas of oncology, radiology and urology with his last being as Vice President of Quality. He was employed by Johnson &
Johnson from 1991 until 1993. He holds a BS-Materials Science and Engineering degree with a concentration in polymer science from North Carolina State University. | 